Cochrane · systematic review · CD006569
Aripiprazole versus other atypical antipsychotics for schizophrenia
Khanna, P, Suo, T, Komossa, K, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
35
current version
GRADE rated
23
No studies
12
Included studies
NR
No studies 12 · 34.3%Ungraded 0 · 0%Very low 18 · 51.4%Low 5 · 14.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsCOMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: No clinically significant response COMPARISON 1. ARIPIPRAZOLE vs CLOZAPINE | RR 1.05 [0.87, 1.27] | 29 studies · 2132 participants | Low Downgraded: risk of bias, imprecision |
Mental state: as measured by BPRS BPRS (high score = poor) COMPARISON 1. ARIPIPRAZOLE vs CLOZAPINE | no estimate extracted | 5 studies · 426 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Leaving the study early ‐ Any reason COMPARISON 1. ARIPIPRAZOLE vs CLOZAPINE | RR 1.41 [0.46, 4.29] | 3 studies · 240 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life: as measured by WHO‐QOL‐100 WHO‐QOL‐100 (low score = poor) COMPARISON 1. ARIPIPRAZOLE vs CLOZAPINE | no estimate extracted | 2 studies · 132 participants | Very low Downgraded: indirectness |
Adverse effects: extrapyramidal effects COMPARISON 1. ARIPIPRAZOLE vs CLOZAPINE | RR 1.91 [0.75, 4.85] | 8 studies · 520 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
General functioning ‐ not measured COMPARISON 1. ARIPIPRAZOLE vs CLOZAPINE | no estimate extracted | NR | No studies |
Service use ‐ not measured COMPARISON 1. ARIPIPRAZOLE vs CLOZAPINE | no estimate extracted | NR | No studies |
COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: No clinically significant response (as defined by original studies) COMPARISON 2. ARIPIPRAZOLE vs QUETIAPINE | RR 0.92 [0.64, 1.32] | 12 studies · 991 participants | Low Downgraded: risk of bias, imprecision |
Mental state: as assessed by PANSS positive symptom scale score PANSS positive symptom subscale (high score = poor) COMPARISON 2. ARIPIPRAZOLE vs QUETIAPINE | no estimate extracted | 7 studies · 583 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Leaving the study early COMPARISON 2. ARIPIPRAZOLE vs QUETIAPINE | RR 0.8 [0.22, 2.87] | 2 studies · 168 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Quality of life: as measured by WHO‐QOL‐100 COMPARISON 2. ARIPIPRAZOLE vs QUETIAPINE | no estimate extracted | 1 study · 100 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Adverse effects: extrapyramidal symptoms COMPARISON 2. ARIPIPRAZOLE vs QUETIAPINE | RR 2.8 [0.64, 12.31] | 4 studies · 348 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
General functioning ‐ not measured COMPARISON 2. ARIPIPRAZOLE vs QUETIAPINE | no estimate extracted | NR | No studies |
Service use ‐ not measured COMPARISON 2. ARIPIPRAZOLE vs QUETIAPINE | no estimate extracted | NR | No studies |
COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: No clinically significant response (as defined by the original studies) COMPARISON 3. ARIPIPRAZOLE vs RISPERIDONE | RR 1.08 [0.96, 1.21] | 80 studies · 6381 participants | Low Downgraded: risk of bias, imprecision |
Mental state: as measured by BPRS BPRS (high score = poor) COMPARISON 3. ARIPIPRAZOLE vs RISPERIDONE | no estimate extracted | 5 studies · 570 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Leaving the study early COMPARISON 3. ARIPIPRAZOLE vs RISPERIDONE | RR 1.02 [0.79, 1.32] | 12 studies · 1239 participants | Very low Downgraded: imprecision, publication bias |
Quality of life ‐ not measured COMPARISON 3. ARIPIPRAZOLE vs RISPERIDONE | no estimate extracted | NR | No studies |
Adverse effects: extrapyramidal symptoms COMPARISON 3. ARIPIPRAZOLE vs RISPERIDONE | RR 0.39 [0.31, 0.5] | 31 studies · 2605 participants | Low Downgraded: risk of bias, publication bias |
General functioning ‐ not measured COMPARISON 3. ARIPIPRAZOLE vs RISPERIDONE | no estimate extracted | NR | No studies |
Service use ‐ not measured COMPARISON 3. ARIPIPRAZOLE vs RISPERIDONE | no estimate extracted | NR | No studies |
COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: No clinically significant response (as defined by the original studies) COMPARISON 4. ARIPIPRAZOLE vs ZIPRASIDONE | RR 0.97 [0.62, 1.52] | 6 studies · 442 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Mental state: as COMPARISON 4. ARIPIPRAZOLE vs ZIPRASIDONE | no estimate extracted | 1 study · 247 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Leaving the study early COMPARISON 4. ARIPIPRAZOLE vs ZIPRASIDONE | RR 0.94 [0.66, 1.34] | 2 studies · 316 participants | Very low Downgraded: risk of bias |
Quality of life ‐ not measured COMPARISON 4. ARIPIPRAZOLE vs ZIPRASIDONE | no estimate extracted | NR | No studies |
Adverse effects: weight gain COMPARISON 4. ARIPIPRAZOLE vs ZIPRASIDONE | RR 4.01 [1.1, 14.6] | 3 studies · 232 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
General functioning ‐ not measured COMPARISON 4. ARIPIPRAZOLE vs ZIPRASIDONE | no estimate extracted | NR | No studies |
Service use ‐ not measured COMPARISON 4. ARIPIPRAZOLE vs ZIPRASIDONE | no estimate extracted | NR | No studies |
COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: No clinically significant response COMPARISON 5. ARIPIPRAZOLE vs OLANZAPINE | RR 1.06 [0.96, 1.17] | 11 studies · 1739 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Mental state: as COMPARISON 5. ARIPIPRAZOLE vs OLANZAPINE | no estimate extracted | 11 studies · 1500 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Leaving the study early COMPARISON 5. ARIPIPRAZOLE vs OLANZAPINE | RR 1.15 [1.05, 1.25] | 9 studies · 2331 participants | Low Downgraded: risk of bias, imprecision, publication bias |
Quality of life: as COMPARISON 5. ARIPIPRAZOLE vs OLANZAPINE | no estimate extracted | 1 study · 68 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Adverse effects: weight gain COMPARISON 5. ARIPIPRAZOLE vs OLANZAPINE | RR 0.25 [0.15, 0.43] | 9 studies · 1538 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
General functioning ‐ not measured COMPARISON 5. ARIPIPRAZOLE vs OLANZAPINE | no estimate extracted | NR | No studies |
Service use ‐ not measured COMPARISON 5. ARIPIPRAZOLE vs OLANZAPINE | no estimate extracted | NR | No studies |